ALK News

Conference Coverage

Dr Lin Shares Systemic Therapies to Overcome Resistance in ALK+ Lung Cancer

10/05/2021

Jessica J. Lin, MD, presents resistance mechanisms inevitable in developing clinical benefits in systemic therapies for patients with advanced ALK+ lung cancer and how to create combination strategies that can overcome disease progression.

Jessica J. Lin, MD, presents...

10/05/2021

Oncology

Conference Insider

No Survival Benefit With Alectinib vs Crizotinib for ALK+ NSCLC

06/01/2021

According to the final J-ALEX OS analysis results, alectinib yielded no advantage in OS compared with crizotinib in patients with ALK+ NSCLC.

According to the final J-ALEX OS...

06/01/2021

Oncology

News

FDA Approves Lorlatinib for Metastatic ALK+ NSCLC

03/04/2021

The FDA has approved lorlatinib for the treatment of patients with metastatic NSCLC with ALK-positive tumors, as detected by an FDA-approved test.

The FDA has approved lorlatinib...

03/04/2021

Oncology

News

First-Line Lorlatinib Improves PFS Versus Crizotinib for ALK+ NSCLC

01/19/2021

First-line lorlatinib, when compared to crizotinib, demonstrated longer PFS and a higher frequency of intracranial response in previously treated patients with ALK-positive NSCLC.

First-line lorlatinib, when...

01/19/2021

Oncology

News

FDA Approves Crizotinib for Young Patients With Relapsed/Refractory, ALK+ ALCL

01/15/2021

The FDA has approved crizotinib for the treatment of young adults and pediatric patients aged ≥1 year with relapsed or refractory, systemic, ALK-positive ALCL.

The FDA has approved crizotinib...

01/15/2021

Oncology

News

FDA Approves Brigatinib for ALK-Positive NSCLC

05/26/2020

The FDA has approved brigatinib for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC as confirmed by an FDA-approved test.

The FDA has approved brigatinib...

05/26/2020

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology